about
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerThe renal channelopathiesEpidermal growth factor, from gene organization to bedsideCNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesemiaP2X6 Knockout Mice Exhibit Normal Electrolyte HomeostasisUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Genetic causes of hypomagnesemia, a clinical overviewHypomagnesemia: a clinical perspective.Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells.Plasma membrane ion fluxes and NFAT-dependent gene transcription contribute to c-met-induced epithelial scattering.Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy.TRPM6 kinase activity regulates TRPM7 trafficking and inhibits cellular growth under hypomagnesic conditions.The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity.Distal convoluted tubuleEGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockadeDetection of renal tissue and urinary tract proteins in the human urine after space flight.Cellular magnesium homeostasis.Flavaglines Stimulate Transient Receptor Potential Melastatin Type 6 (TRPM6) Channel ActivityPhosphatidylinositol 4,5-bisphosphate (PIP(2)) controls magnesium gatekeeper TRPM6 activity.Regulation of magnesium balance: lessons learned from human genetic diseaseTRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions.Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels.Role of renal TRP channels in physiology and pathologyDeficiency of renal cortical EGF increases ENaC activity and contributes to salt-sensitive hypertension.Identification of SLC41A3 as a novel player in magnesium homeostasis.Epidermal growth factors in the kidney and relationship to hypertension.Hereditary tubular transport disorders: implications for renal handling of Ca2+ and Mg2+.Molecular identification of ancient and modern mammalian magnesium transporters.Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells.C. elegans TRP channels.Drug-induced alterations in Mg2+ homoeostasis.Disorders of calcium and magnesium balance: a physiology-based approach.Inherited disorders of renal hypomagnesaemia.Magnesium and disturbances in carbohydrate metabolism.Regulation of Mg2+ Reabsorption and Transient Receptor Potential Melastatin Type 6 Activity by cAMP Signaling.Inherited and acquired disorders of magnesium homeostasis.Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling.Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6.Genetics of Magnesium Disorders.Segmental transport of Ca²⁺ and Mg²⁺ along the gastrointestinal tract.
P2860
Q26747335-A1BB8E2A-002E-4DF1-82E8-89DAFB890978Q26824023-D9026E66-BF33-4725-A0C4-DDF2F40B2A45Q26865616-7CC16C38-550B-4989-8A8A-49F961E96DD4Q27316532-7BBE80D0-F069-4916-A6BF-EC020F172DC5Q27341945-7183A88B-3F78-4149-8E79-CEA955514C4DQ33408049-297A843E-9EA1-4997-A558-D19B5CEC7E53Q33715342-3C486BA0-B87F-4B86-A978-A90EB75518ADQ33774122-37B9128F-E3E1-4374-83BF-254B33E98DF6Q34267140-D194C5FA-AD06-44D7-AD26-36FCDDB90F46Q34299312-3A16C669-7C18-452D-A3A1-62CEACEFF34DQ34317153-CB83B3A3-4896-43BD-9568-17D3C6C680A1Q34527118-854F7514-3C8F-4354-8C13-C45371C818DFQ34607236-48DC16EC-B463-4C4C-BBED-B7596E8E031AQ34629804-313FBFF5-5147-4503-B4F8-7AF608D06135Q34859831-1857C2DE-6DAE-4ED6-B038-AA510D336074Q34964281-92C9E781-A18E-4638-9099-822B2DEB9E93Q35096887-9407CFB0-9558-4FA8-9607-789FF4C9D719Q35182091-0B6140CF-2D58-4F9D-8040-05CA92209FBEQ35614894-A6F9B39F-C83E-4D6F-9F55-2A780DD1DC00Q35683775-EE657519-433B-4D50-A0FD-5B5F0042181AQ36444424-45C46DEC-C456-4C0E-9977-D76DED7F3AABQ36508597-6EB63FCC-C402-426B-91C9-79B6A455A26FQ36703547-4EC754A0-5635-4FC1-A836-FA4AFF501F97Q36977357-73DEAEB3-57D9-458E-B731-0CA37C399A33Q37044436-1636E0B6-FDC4-437A-A617-11379F770953Q37051477-7D941BEB-4C89-4826-9CFF-3CAB2829D731Q37603366-7396E6A8-B9F7-43AC-9CEE-7AA75EFAA899Q37638953-D4C41ED2-E5E2-423E-A467-CD5881661291Q37801469-3D67FDDB-44F2-4278-A45F-4BAF39297E2AQ37835131-3D64A544-00D0-4A2D-88AE-EA5DD8E5094FQ37992700-D0800FB3-E9BE-4239-BB54-EEB7ECC9C7B4Q38059082-7EFE30E2-8DFB-430F-A32D-2196B468CA21Q38244120-BAFACDEC-0E3F-4B3D-9AE4-65F7BAFDD55EQ38479670-0777D5D8-D165-49D7-B7BC-0BEBCE0185C5Q38654032-81F82DA0-D721-4075-8D62-77E547902625Q39025913-E10ACB0E-F652-4308-ADA3-8E4548D286FFQ42173242-0375EEA4-ECBB-461E-A3CF-8469DAEE67B3Q43457054-41A12E23-5F40-4D76-9141-2D18E36740FFQ47726302-F811A7E8-7B61-4D50-A709-AEC1CD1C4018Q48248010-B216BE97-F37E-4F25-BD54-A79C3E2F0A2E
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
EGF increases TRPM6 activity and surface expression.
@en
EGF increases TRPM6 activity and surface expression.
@nl
type
label
EGF increases TRPM6 activity and surface expression.
@en
EGF increases TRPM6 activity and surface expression.
@nl
prefLabel
EGF increases TRPM6 activity and surface expression.
@en
EGF increases TRPM6 activity and surface expression.
@nl
P2093
P2860
P356
P1476
EGF increases TRPM6 activity and surface expression.
@en
P2093
Joost G Hoenderop
R Todd Alexander
René J Bindels
Stéphanie Thebault
Wouter M Tiel Groenestege
P2860
P356
10.1681/ASN.2008030327
P577
2008-12-10T00:00:00Z